Home › Compare › VIRI vs RYLD

VIRI vs RYLD: Dividend Comparison 2026

VIRI yields 1290.32% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIRI wins by $2.3960825995340865e+24M in total portfolio value
10 years
VIRI
VIRI
● Live price
1290.32%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.3960825995340865e+24M
Annual income
$2,395,725,921,261,555,500,000,000,000,000.00
Full VIRI calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — VIRI vs RYLD

📍 VIRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIRIRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIRI + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VIRI pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIRI
Annual income on $10K today (after 15% tax)
$109,677.42/yr
After 10yr DRIP, annual income (after tax)
$2,036,367,033,072,322,200,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, VIRI beats the other by $2,036,367,033,072,322,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIRI + RYLD for your $10,000?

VIRI: 50%RYLD: 50%
100% RYLD50/50100% VIRI
Portfolio after 10yr
$1.1980412997670432e+24M
Annual income
$1,197,862,960,630,777,700,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is split right now

VIRI
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-882.0
Piotroski
1/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIRI buys
0
RYLD buys
0
No recent congressional trades found for VIRI or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIRIRYLD
Forward yield1290.32% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓0%
Portfolio after 10y$2.3960825995340865e+24M$44.5K ✓
Annual income after 10y$2,395,725,921,261,555,500,000,000,000,000.00 ✓$2,587.35
Total dividends collected$2.3960592593715676e+24M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VIRI vs RYLD ($10,000, DRIP)

YearVIRI PortfolioVIRI Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$268,765$258,064.52$11,914$1,213.65+$256.9K → VIRI
2$13,251,799$12,964,221.46$14,099$1,351.30+$13.24M → VIRI
3$1,208,980,447$1,194,801,021.45$16,580$1,494.55+$1208.96M → VIRI
4$205,038,263,945$203,744,654,866.63$19,384$1,642.61+$205038.24M → VIRI
5$64,806,832,428,888$64,587,441,486,467.30$22,535$1,794.70+$64806832.41M → VIRI
6$38,226,866,599,812,776$38,157,523,289,113,870.00$26,063$1,950.00+$38226866599.79M → VIRI
7$42,111,076,145,403,994,000$42,070,173,398,142,190,000.00$29,995$2,107.69+$42111076145403.96M → VIRI
8$86,671,038,474,809,380,000,000$86,625,979,623,333,790,000,000.00$34,361$2,266.99+$86671038474809392.00M → VIRI
9$333,344,179,935,764,700,000,000,000$333,251,441,924,596,600,000,000,000.00$39,194$2,427.12+$333344179935764676608.00M → VIRI
10$2,396,082,599,534,086,500,000,000,000,000$2,395,725,921,261,555,500,000,000,000,000.00$44,525$2,587.35+$2.3960825995340865e+24M → VIRI

VIRI vs RYLD: Complete Analysis 2026

VIRI — Stock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Full VIRI Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this VIRI vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIRI vs SCHDVIRI vs JEPIVIRI vs OVIRI vs KOVIRI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.